Sensorion SA, Annual General Meeting, May 11, 2026 Apr 07
Sensorion Reports Six-Month Update from the Audiogene Phase 1/2 Trial of SENS-501 and Advances GJB2-GT (SENS-601) Toward First-In-Human Clinical Development Mar 23
Sensorion SA has filed a Follow-on Equity Offering in the amount of €60 million. Jan 30
Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501'S Audiogene Phase 1/2 Trial Dec 09
Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial Jul 29
Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial Jul 02
Sensorion SA, Annual General Meeting, May 12, 2025 Apr 05
Sensorion Announces Board Changes Apr 02
Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of Sens-401 for the Prevention of Cisplatin-Induced Ototoxicity Mar 07
Sensorion Receives Positive Recommendation from Data Monitoring Committee of Sens-501’S Audiogene Phase 1/2 Clinical Trial Feb 21
Sensorion Announces Completion of Enrollment of the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial Dec 27
Sensorion Reports Data in the Audiogene Phase 1/2 Gene Therapy Clinical Trial Dec 18
Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity Jul 23
Sensorion Announces New Positive Secondary Efficacy Endpoints Data from Sens-401 Phase 2A Clinical Trial for the Preservation of Residual Hearing Loss Jul 15
Sensorion Announces Appointment of Laurene Danon as Chief Financial Officer Jun 27
Sensorion SA, Annual General Meeting, May 29, 2024 May 08
Sensorion SA has completed a Follow-on Equity Offering in the amount of €15.482057 million. Apr 09
Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation Mar 11
Sensorion SA to Report Fiscal Year 2023 Results on Mar 14, 2024 Feb 20
Sensorion Announces the Completion of Patient Inclusion in Phase 2A Clinical Trial of Sens-401 for Residual Hearing Preservation After Cochlear Implantation Feb 01
Sensorion Appoints Federico Mingozzi as Non-Executive Director to the Board of Directors Jan 25
Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate Sens-501 into a Phase 1/2 Clinical Trial in Some European Countries Jan 19
Sensorion SA Appoints Bernd Schmidt as New Chief Technical Officer Dec 12
Sensorion SA, Annual General Meeting, Dec 20, 2023 Nov 30
Sensorion SA announced that it has received €33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC Sep 21
Sensorion SA to Report Q2, 2023 Results on Sep 18, 2023 Sep 20
Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe Jul 21
Sensorion Sa Submits Clinical Trial Application for Lead Gene Therapy Candidate Otof-Gt in the Uk Jul 12
Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study Jul 06
Sensorion SA Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity Jan 03
Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to Otof-Gt for the Treatment of Otoferlin Gene-Mediated Hearing Loss Nov 07
Sensorion SA Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France Oct 24
Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation Sep 14
Sensorion SA to Report First Half, 2022 Results on Sep 22, 2022 Aug 10
Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation Jul 02
Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation Jun 07
Sensorion SA, Annual General Meeting, May 31, 2022 May 10
Sensorion SA to Report Fiscal Year 2021 Results on Oct 31, 2022 Apr 14
Sensorion SA Updates on SENS-401 Phase 2 Trial in Sudden Sensorineural Hearing Loss Jan 18
Sensorion Announces Regulators Approval for Sensorion’s Amendment to Phase 2 Audible-S Trial of SENS-401 in Sudden Sensorineural Hearing Loss Sep 24
Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021 Feb 19
Sensorion Announces Third Gene Therapy Collaboration with Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments Feb 16
Sensorion Announces Preclinical Data Demonstrating SENS-401's Potential to Preserve Residual Hearing After Cochlear Implantation Jan 20
Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss Jan 06
Sensorion SA announced that it expects to receive €4.999999 million in funding from Sonova Holding AG Dec 16
Sensorion and Novasep Announce Signature of A Gene Therapy Product Development and Manufacturing Agreement Oct 27
Sensorion SA has completed a Follow-on Equity Offering in the amount of €31.0012 million. Sep 18